Amicus Therapeutics priced its newly-approved...

...Fabry disease treatment, Galafold, at an average of $315,000 per year. The drug will compete with Sanofi SA's Fabrazyme, another enzyme-replacement therapy. Fabrazyme holds preferred-tier status for 22% of all commercial lives, and 42% of all commercial lives have unrestricted access to the drug.